Immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder characterized by abnormally low platelet counts. We reported here the ability of low-level light treatment (LLLT) to alleviate ITP in mice. The treatment is based on noninvasive whole body illumination 30 min a day for a few consecutive days by near infrared light (830 nm) transmitted by an array of light-emitting diodes (LEDs). LLLT significantly lifted the nadir of platelet counts and restored tail bleeding time when applied to two passive ITP models induced by anti-CD41 antibody. The anti-platelet antibody hindered megakaryocyte differentiation from the progenitors, impaired proplatelet and platelet formation, and induced apoptosis of platelets. These adverse effects of anti-CD41 antibody were all mitigated by LLLT to varying degrees, owing to its ability to enhance mitochondrial biogenesis and activity in megakaryocytes and preserve mitochondrial functions in platelets in the presence of the antibody. The observations argue not only for contribution of mitochondrial stress to the pathology of ITP, but also clinical potentials of LLLT as a safe, simple, and cost-effective modality of ITP.
INTRODUCTION
Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disorder, characterized by a transient or persistent decline of circulating platelets and the absence of other conditions known to induce thrombocytopenia. Its overall incidence is between 1.9 and 6.4 per 10 5 children and 3.3 per 10 5 adults annually 1 . Signs and symptoms of ITP vary widely with patients. Most of them have either no symptoms or minimal bruising, whereas others may experience serious bleeding, including extensive skin, mucosal, gastrointestinal or intracranial hemorrhage 2 . ITP patients are primarily treated by corticosteroids as a first-line therapy with response rates of 70-90%. However, long-term use of corticosteroids is not recommended due to side effects such as gastrointestinal distress and osteoporosis 3, 4 . The majority of patients treated with corticosteroid relapses during drug tapering or after withdrawal, and thus requires further therapy 5 . One of the standard second-line therapies is splenectomy, which offers approximately 60% long-term stable response rate but with an increased risk for postoperative complications 6, 7 . In recent years, antibody against B cells named rituximab and thrombopoietin (TPO) receptor agonists like eltrombopag and romiplostim serve as second-line options with good tolerance and promising response rates 8, 9 . Spleen tyrosine kinase inhibitors such as fostamatinib that is in phase III clinical trials might also offer another therapy for ITP. However, rituximab sometimes increased susceptibility to infections and neutropenia 10, 11 . Clinical study showed that long-term treatment with eltrombopag or romiplostim could trigger some adverse effects, including liver enzyme elevation, thrombolic events and increased bone marrow reticulin 12, 13 . Furthermore, these second-line drugs are all very expensive. We aimed at development of a simple, safe, and cost-effective alternative to manage ITP.
Low-level light refers to red to near infrared lasers with a wavelength of 600-1,100 nm, an output power of 1-500 mW, and relatively low energy densities (0.04-50 J/cm 2 ), in either a continuous wave or pulsed mode. It has been used in the clinics for decades in wound healing, tissue repair, pain relief, and inflammation reduction with a long safety record [14] [15] [16] [17] . Mitochondrial cytochrome c oxidase is currently thought to be one of the major photoacceptors for the initial effects of low-level light 18 . Several investigators, including us, have shown that low-level light treatment (LLLT)
modulates ATP production, reactive oxygen species (ROS) formation, apoptosis, cellular metabolic process, and signaling transduction pathways secondarily to more sufficient function of mitochondria under various conditions of stress [19] [20] [21] . Recently, we discovered that 810-nm continuous wave diode laser at 30 J/cm 2 could penetrate into mouse bone marrow noninvasively without incurring any significant heat 22 . Noninvasive whole body illuminations with the LLLT cured acute thrombocytopenia induced by irradiation, chemotherapeutic drug, or anti-CD41 antibody much faster than sham-light treatment 23 . We found that LLLT bolstered mitochondrial biogenesis predominantly in polyploid megakaryocytes (MKs), increasing platelet production both in vivo and in vitro 24 . In the current study, we apply an array of light-emitting diodes (LEDs), instead of diode laser, to two passive ITP mouse models to gain similar results. In comparison with diode laser, LED is safer and more convenient and cost-effective. Moreover, an LED array can illuminate a relative large area of the body in a hands-free manner, in sharp contrast to a point-by-point application of a laser system 25 . LED illumination appears as effectively as a diode laser in ITP amelioration.
RESULTS

LLLT ameliorates ITP
To investigate thrombopoietic effects of LLLT, we used a passive ITP mouse model by daily injecting anti-CD41 antibody at 0.1 mg/kg body weight. The mice were then treated with either sham light or 830-nm LED at 36 J/cm 2 in 4 hours after anti-CD41 antibody injection and the similar LLLT continued once a day up to 5 days. Platelet counts were enumerated daily before each antibody injection. As shown in Figure 1a , a single dose of anti-CD41 antibody diminished platelet counts by 40% in ITP+sham group compared with the control group. LLLT lifted the nadir effectively by only two treatments (P<0.01) in ITP+LLLT group when compared to ITP+sham group. Continuous LLLT daily greatly prevented a loss of platelets and sustained platelet counts above 60% of the control, whereas the mice remained severely thrombocytopenic in ITP+sham group, with platelet counts below 50% of the control (P<0.01 on day 2; P<0.05 on day 3;
and P<0.05 on day 4). Moreover, bleeding time in ITP+sham group was lengthened to 120 sec from 50 sec in the control group on day 2 (P<0.01, Figure 1b) , and LLLT shortened the bleeding time by 50%, leading to a nearly normal level in ITP+LLLT group (P<0.01, Figure 1b) . We then extended our investigation to another ITP model by administering anti-CD41 antibody twice one on day 0 and the other on day 3 each at 0.5 mg/kg body weight. The mice were treated with sham light or LLLT daily from day 0 to day 4 ( Figure 1c ). The antibody once again lowered platelet counts significantly one day after, and platelet counts reached the nadir in 3~4 days with an ~60% decline and remained significantly lower up to day 6 in ITP+sham group. The decline of platelet counts was however largely prevented by daily LLLT for 5 days, concurrent with normalization of bleeding time in the mice on day 4 in ITP+LLLT group (Figure 1d ). The result confirms that LLLT restores not only platelet counts but also platelet function in mice receiving anti-CD41 antibody.
LLLT partially reverses antibody-mediated inhibition of MK differentiation
To address the mechanism underlying thrombopoietic effect of LLLT, mouse bone marrow nucleated cells were . This biphasic dose-response of LLLT was also reported previously in LLLT-mediated ATP synthesis and recovery of traumatic brain injury 26, 27 . The finding that antibody-mediated inhibition of MK differentiation can be significantly reversed only after multiple doses of LLLT may be due to its accumulative effect on a specific differentiation stage of MKs, which is supposed to be continuously formed throughout the 3-day differentiation culture. The ability of LLLT to partially reverse the antibody-mediated inhibition of MK differentiation may contribute, at least in part, to its mitigation of ITP in vivo ( Figure 1 ).
LLLT improves proplatelet and platelet formation in the presence of anti-CD41 antibody
Apart 
LLLT enhances mitochondrial function and biogenesis in antibody-treated MKs
Our recent study showed that LLLT bolstered ATP production and mitochondrial biogenesis in MKs 28 . 
LLLT prevents platelet apoptosis and prolongs its lifespan
In light of a well-documented role for mitochondrial activity in the lifespan of platelets 29 , we next determined whether LLLT could protect platelets from apoptosis and prolong their lifespan, an yet another factor contributing to mitigation of ITP by LLLT seen in Figure 1 . To this end, platelets were prepared from mouse blood samples, cultured in MK medium, and treated with or without anti-CD41 antibody for 2 hr before exposure of the platelets to LLLT. Measurement of the caspase-3/7 activity in the platelets revealed a 3.6-fold increase in caspase-3/7 activity, on average, in the presence compared to the absence of anti-CD41 antibody (P<0.001, Figure 5a ). The antibody-induced activation of caspase3/7 was profoundly blunted by LLLT when measured 6 hr post-LLLT (P<0.001, Figure 5a ). This ex vivo observation was subsequently corroborated in vivo in the passive mouse ITP model treated with LLLT daily at 36 J/cm 2 as Figure 1a . As shown in Figure 5b , daily injection of anti-CD41 antibody led to about 5.6-fold increases in the percentage of platelets expressing activated caspase-3 (p<0.01, Figure 5b ), when platelets were isolated from the mice on day 2 after antibody injection and assayed for caspase-3 activation. However, the proportion of apoptotic platelets declined to a near normal level by two doses of noninvasive whole body LLLT of the mice (P<0.01, Figure 5b ). Since platelet apoptosis is correlated with platelet lifespan and clearance 30 , we monitored circulating platelets in these mice after injection of a biotinylation agent as previously described 31 , which is a common assay for monitoring the lifespan of platelets in the circulation. In comparison with control mice, the percentage of biotin-labeled platelets was decreased precipitously on day 2 and day 3 and remained below a 50% level on day 3 in ITP+sham mice (Figure 5c ). In contrast, LLLT was able to sustain biotin-labeled platelets at normal levels, increasing biotin-labeled platelets to 87% from 60% on day 2 (P<0.001, Figure 5c ) and to 56% from 40% on day 3 (P<0.01, Figure 5c ). These results suggest that LLLT prevents platelets from apoptosis and prolongs their lifespan in the presence of anti-platelet antibody.
DISCUSSION
The current investigation demonstrates the ability of LLLT to alleviate thrombocytopenia in two ITP mouse models 32 , which are different from the one we recently tested 33 . While both studies consistently show a potential of LLLT to be a novel modality to treat thrombocytopenia, the current study is tailored specifically for ITP, especially how LLLT can correct the adverse effect of anti-platelet antibody on platelet biogenesis and the survival of platelets. Anti-CD41
antibody appears to impair multiple discernible differentiation steps of platelet biogenesis, including MK differentiation from the progenitors, proplatelet formation, platelet generation, and the survival of platelets. Strikingly, LLLT is able to ameliorate all of these defects caused by anti-CD41 antibody at varying degrees through enhancing mitochondrial activity and/or biogenesis, resulting in ITP alleviation and restoration of tail bleeding time in antibody-treated mice. The study underscores contribution of mitochondrial stress either directly or indirectly to the pathology of ITP, which may open novel avenues for ITP management, for instance, by using mitochondrion-promoting drugs.
A loss of immune tolerance to self-antigens is believed resulting in development of various autoantibodies against platelets, MKs, and MK progenitors 34 . These autoantibodies impair MK differentiation and platelet generation and destroy platelets, leading to a low platelet count. The impaired megakaryocytopoiesis and platelet production in ITP pathogenesis have been demonstrated in several animal models and MK morphologic studies 35, 36 . In vitro cell culture studies have shown that plasma of ITP patients hinders MK differentiation 37-39 and in some instances also inhibits proplatelet formation 40 because the plasma contains autoantibodies directed at platelets. Similarly, we found that anti-CD41 antibody hampered MK differentiation, proplatelet formation, and platelet generation in a dose-dependent manner The observations argue not only for mitochondrial stress as one of the etiologies of ITP but also for the mechanism underlying LLLT-mediated alleviation of ITP.
Apart from inhibition of MK differentiation and platelet formation, anti-platelet antibody appears to induce apoptosis of platelets, which may be another factor contributing to the immunopathology of ITP 34, 54, 55 . Anti-platelet autoantibody has been shown to increase mitochondrial inner membrane potential (∆ψ m ) depolarization, caspase-3,8,9 activation and phosphatidylserine exposure in platelets 56, 57 , indicating a mitochondrion-dependent apoptosis pathway involved. In support of a role for platelet apoptosis in ITP pathogenesis, caspase-3 activation is greatly elevated in platelets by anti-CD41 antibody, shortening the lifespan of circulating platelets. On the contrary, LLLT significantly inhibits platelet apoptosis, and prolongs platelet lifespan, a finding that is not reported in our previous study 58 . The mechanism underlying LLLT-mediated protection against apoptosis of platelets is likely associated with the ability of LLLT to protect mitochondrial functions in the presence of anti-CD41 antibody.
LLLT has been a therapeutic approach for analgesics, anti-inflammation and wound healing in the clinics for 30 years with a long recorded safety. Although the current study primarily targets thrombocytopenia induced by anti-CD41
antibody, LLLT-mediated enhancement of platelet production should be extended to ITP caused by other etiologies, such as anti-CD42b antibody or pathogenic T/B cell reactivity 59,60 , as well as to those acquired thrombocytopenia that are not mediated by an immune mechanism including HIV, chemotherapy, and irradiation-induced thrombocytopenia 61 .
METHODS
Mice
C57BL/6 mice at 6-8 weeks of age were purchased from Charles River Laboratories. The mice were maintained in a 12-hour light/dark cycle. The animal protocol was approved by the subcommittee on Research Animal Care of the Massachusetts General Hospital. All animal experiments in this study were performed according to the National Institutes of Health guidelines for the Care and Use of Laboratory Animals.
ITP induction
Mice were intraperitoneally injected with anti-CD41 antibody (BD Bioscience) either daily at 0.1 mg/kg body weight in PBS or on day 0 and 3 only each at 0.5 mg/kg body weight. Control mice were intraperitoneally injected with 400 μL PBS in parallel. Platelet counts were analyzed on a HemaTrue veterinary hematology analyzer (Heska Corporation) with 50 μL whole blood collected from the retro-orbital venous plexus into EDTA-coated microtainer tubes (BD Bioscience).
Low-level light treatment
LLLT was performed by an array of near infrared LEDs at 830 nm (Photo Therapeutics, Inc). For whole body illumination of a mouse, the hair-removed mouse was subject to LED irradiation at 4 hr after anti-CD41 antibody injection. The average irradiance of LED was 20 mW/cm 2 and the total exposure time was 30 minutes to achieve an energy density of 36 J/cm 2 . For in vitro studies, MK or platelet cultures were exposed to LED at 2 hr after anti-CD41
antibody incubation, with an average irradiance of 20 mW/cm 2 and different energy densities specified in each experiment. The sham light was administered similarly with a small soft white LED light bulb (3W, A15) from General
Electric.
Bleeding time analysis
Tail bleeding time was determined as previously described 31 . Briefly, the tail was transected at 5 mm from the tip while the mouse was strained in a restrainer (Braintree Scientific). The bleeding tail was immersed in a 15-ml test tube containing 37°C pre-warmed PBS. Then the time to cessation was measured.
MK differentiation from bone marrow cells
Bone marrow cells were flushed from femur and tibia of the mice by Hanks' balanced salt solution (HBS, Sigma)
supplemented with 100 U/mL penicillin-streptomycin (Life Technologies), and filtered through a 100-μm strainer. After removal of red blood cells using ACK lysing buffer (Quality Biological), the cells were seeded in 6-well plates at a concentration of 1×10 6 cells/mL in StemSpan serum-free expansion medium (STEMCELL Technologies) supplemented with 100 ng/ml TPO and differentiated for indicated days. 
Platelet lifespan analysis
Platelet lifespan was monitored by in vivo biotinylation as previously described 31 . In brief, 3mg EZ-link-NHydroxysulfosuccinimide-Biotin (EZ-NHS-Biotin, Pierce) was intravenously injected into each mouse. Blood samples were obtained at indicated days and incubated with FITC-anti-CD41 and phycoerythrin (PE)-conjugated streptavidin (Biolegend), followed by flow cytometric analysis of biotinylated platelets.
Statistical analysis
Statistical significance was assessed by two-tailed student's t test for two-group comparison or one way analysis of variance (ANOVA) for multiple-group comparison using Graphpad Prism 6.0 (Graphpad Software). A value of P< 0.05 was considered statistical significance. Platelets were biotinylated in vivo, followed by ITP induction and LLLT as Figure 1A . The percentage of biotin-labeled platelets in the circulation was determined by flow cytometry before each antibody injection. All data represent mean ± SEM; n=12; ns, no significance; and *P<0.05, **P<0.01, ***P<0.001 compared in the presence or absence of LLLT or anti-CD41 antibody.
